#Vienna #Austria #RNA Sequencing #Lexogen #Ochre Bio

Lexogen Completes Major Sequencing Project with Ochre Bio

Lexogen, a prominent biotechnology firm based in Vienna, has recently announced the successful completion of an extensive project aimed at generating significant data sets from primary human hepatocytes. This initiative, carried out in collaboration with Ochre Bio, revolved around next-generation sequencing (NGS) technologies, which are pivotal for advancing the understanding and treatment of chronic liver diseases.

The ambitious project encompassed over 120,000 samples, all subjected to Lexogen’s proprietary gene expression profiling platform. Utilizing advanced RNA transcriptomics, Lexogen has set a new benchmark in high-resolution analysis that does not require extraction, enabling effective profiling at an unprecedented scale. The company’s efforts were specifically tailored to support Ochre Bio, a biotechnology entity focused on developing RNA medicines for under-treated chronic liver diseases.

Ochre Bio specializes in creating and integrating extensive human liver data that includes gene perturbation and disease atlases. This enables insightful predictions regarding causal pathways for target discovery, ultimately aiding the development of RNA therapies. To facilitate this, Ochre employs its proprietary OBELiX software, designed to interrogate gene biology within human cells and tissues. This software serves as an AI-driven discovery engine, ranking targets based on biological relevance.

The reliability of high-fidelity RNA-Seq data acts as a cornerstone for Ochre's human discovery platform. Over the years, Lexogen has emerged as a dependable long-term sequencing partner for Ochre, consistently delivering high-quality RNA sequencing data from various biological inputs, ranging from bio-banked FFPE to micro-organ and primary hepatocyte samples. All NGS services provided by Lexogen align with current good laboratory practices (cGLP), ensuring adherence to rigorous standards. Moreover, Lexogen's proprietary technology is designed and manufactured under ISO 13485 compliance in Vienna, guaranteeing reliable and high-standard outputs.

According to Quin Wills, CEO and Founder of Ochre Bio, “In AI-driven target discovery, a platform is only as powerful as the data fueling it. With over 120,000 samples from primary human hepatocytes, the complexity necessitates stringent data quality and cross-sample consistency. Only through high-fidelity sequencing can we extract meaningful insights crucial for model training.” This emphasizes Lexogen’s role in equipping Ochre with indispensable high-quality data that enhances biological signal clarity, helping in machine-learning applications designed to differentiate genuine biological signals from technical noise.

On Lexogen's side, CEO Stephane Barges remarked, “Our team is wholly committed to delivering high-quality services at scale for our partners. We focus on ensuring reliable and accurate data throughout the process, which is vital not only for our clients but ultimately for improving patient healthcare outcomes.” His comments highlight Lexogen’s dedication to innovation and supporting therapies, which bring tangible benefits to patient care.

Lexogen has been in operation for nearly two decades, continually providing innovative solutions in transcriptome analysis and RNA sequencing. Their offerings include various kits, reagents, bioinformatics tools, and bespoke services (CRO), all tailored to meet the needs of the research community. The strict quality controls and compliance standards set by Lexogen underscore their commitment to advancing the fields of biotechnology and healthcare, sustainably.

For further information about Lexogen and its cutting-edge solutions, please visit their official website at www.lexogen.com or follow them on social media @lexogen.